Results 171 to 180 of about 1,505,677 (242)

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

The psychometric properties of validated tools to assess cannabis use disorder: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung, Daniel Stjepanovic, Stephanie Fong, Danielle Dawson, Giang Vu, Tesfa Yimer, Caitlin McClure‐Thomas, Wayne Denis Hall, Gary Chung Kai Chan   +8 more
wiley   +1 more source

Opioid Crisis

International Journal of Pharmacy Research & Technology, 2018
openaire   +2 more sources

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

The Nightmare of the Opioid Crisis in America [PDF]

Archives of Psychiatric Nursing, 2019
openaire   +2 more sources

Reducing opioid use for chronic pain with a group‐based intervention: Economic evaluation using randomised controlled trial data

Addiction, EarlyView.
Abstract Background and aims Long‐term strong opioid use for chronic non‐malignant pain (CNMP) represents a significant public health challenge, associated with reduced health‐related quality of life (HRQoL) and increased mortality. The Improving the Wellbeing of people with Opioid Treated CHronic pain (I‐WOTCH) trial demonstrated that a multicomponent
Sheeja Manchira Krishnan, Vijay S. Gc, Tom Bromilow, Joe W. E. Moss, Katie Booth, Harbinder K. Sandhu, Andrea Manca, Cynthia Paola Iglesias Urrutia, on behalf of the I‐WOTCH team, Harbinder Kaur Sandhu, Sam Eldabe, Charles Abraham, Sharisse Alleyne, Shyam Balasubramanian, Lauren Betteley, Katie Booth, Dawn Carnes, Andrea Dompieri Furlan, Sam Eldabe, Kirstie Haywood, Maddy Hill, Ranjit Lall, Andrea Manca, Dipesh Mistry, Vivien Patricia Nichols, Jennifer Noyes, Anisur Rahman, Kate Seers, Jane Shaw, Nicole Kit Yee Tang, Stephanie Taylor, Colin Tysall, Martin Underwood, Emma Withers, Cynthia Paola Iglesias Urrutia   +34 more
wiley   +1 more source

The impact of harm reduction interventions on injection‐related bacterial infections among people who inject drugs: A systematic review

Addiction, EarlyView.
Abstract Background and aims Injection‐related bacterial infections represent a major but under‐recognised health issue among people who inject drugs (PWID). Harm reduction interventions (HRIs) like needle and syringe programmes (NSP) and opioid agonist treatment (OAT) could mitigate their burden.
Anthony Cousien, Lobna Tijani, Nadia Hachicha, Manon Godart, Mathieu Castry, Karen Champenois, Perrine Roux, Sylvie Deuffic‐Burban   +7 more
wiley   +1 more source